Skip to contentM
Marker Therapeutics, Inc.
M
MRKRMarker Therapeutics, Inc. Q1 2023 · 10-Q
Revenue$1.23M$1.23M+28.0% vs Q1 2022 Net Income-$4.97M-$4.97MN/M vs Q1 2022 EPS Diluted-$0.57-$0.57N/M vs Q1 2022 Operating Income-$4,309,479N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Marker Therapeutics, Inc. · CIK 1094038 · Engraved from SEC EDGAR
Margins · derivedOperating margin-349.1%+666.6 pt vs Q1 2022
Net margin-402.4%+625.3 pt vs Q1 2022
ended Mar 31, 2023 · filed May 15, 2023 · 45 d after period end